Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 8911 results

  1. Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Nifedipine - Lidocaine for Chronic Anal Fissure [TSID 12093]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Subcutaneous nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID 12178]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Cyanoacrylate glue for hernia mesh fixation (MT707)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  5. O2Matic pro 100 (MT746)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  7. Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Modified release hydrocortisone capsules for treating adrenal insufficiency in people 12 years and over [TSID12254]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Dasiglucagon for treating severe hypoglycaemia caused by type 1 diabetes in people under 6 years [TSID12255]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Lebrikizumab for treating atopic dermatitis in children [TSID12133]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation